Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 2/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butylbenzene SCHEMBL22264597 | 1.00 | MAPK1 (0.55) | MAPK1TSHRALDH1A1TAAR1LMNA | |
| Tert-Butylbenzene SCHEMBL18889 | 1.00 | MAPK1 (0.55) | MAPK1TSHRALDH1A1TAAR1LMNA | |
| Tert-Butylbenzene SCHEMBL337648 | 1.00 | MAPK1 (0.55) | MAPK1TSHRALDH1A1TAAR1LMNA | |
| Tert-Butylbenzene SCHEMBL22264599 | 1.00 | MAPK1 (0.55) | MAPK1TSHRALDH1A1TAAR1LMNA | |
| Tert-Butylbenzene SCHEMBL16583175 | 0.97 | MAPK1 (0.52) | MAPK1TSHRALDH1A1TAAR1LMNA | |
| Tert-Butylbenzene SCHEMBL309340 | 0.97 | LMNA (0.55) | MAPK1TSHRALDH1A1TAAR1LMNA | |
| Tert-Butylbenzene SCHEMBL11852689 | 0.97 | MAPK1 (0.52) | MAPK1TSHRALDH1A1TAAR1LMNA | |
| Tert-Butylbenzene SCHEMBL975494 | 0.97 | MAPK1 (0.52) | MAPK1TSHRALDH1A1TAAR1LMNA | |
| Tert-Butylbenzene SCHEMBL6537004 | 0.97 | MAPK1 (0.52) | MAPK1TSHRALDH1A1TAAR1LMNA | |
| Tert-Butylbenzene SCHEMBL5921915 | 0.97 | MAPK1 (0.52) | MAPK1TSHRALDH1A1TAAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2511267-A1 | 3-((N-ACYLATED AMINOACYL)AMINO)PYRAZOLES AS INHIBITORS OF BETA-AMYLOID PEPTIDE PRODUCTION USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-1994019-B1 | NOVEL PIPERIDIN - SUBSTITUTED INDOLES AND THEIR USE AS CCR-3 MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20100280066-A1 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | TUNG JAY S | 2010-11-04 | — | — | US | disclosed |
| US-7759365-B2 | Piperidine-substituted indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7759382-B2 | such as N-{5-[1-(4-chloro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, used for inhibiting beta-amyloid peptide release and/or biosynthesis, inhibiting gamma-secretase activity, prevention and treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| EP-1633350-A4 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | ELAN PHARM INC (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1994019-A2 | NOVEL PIPERIDIN - SUBSTITUTED INDOLES AND THEIR USE AS CCR-3 MODULATORS | Boehringer Ingelheim International GmbH (DE) | 2008-11-26 | — | — | EP | disclosed |
| US-7358396-B2 | Preparation of optically active amines | BASF AKTIENGESELLSCHAFT (DE) | 2008-04-15 | — | — | US | disclosed |
| US-20070197624-A1 | Acylated amino acid amidyl pyrazoles and related compounds | ELAN PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070155971-A1 | Chiral diphosphorus compounds and their transition metal complexes | Source Global, PBC | 2007-07-05 | — | — | US | disclosed |
| US-20040127430-A1 | Chiral monophosphorus compounds and their transition metal complexes | LANXESS DEUTSCHLAND GMBH (DE) | 2004-07-01 | — | — | US | disclosed |
| EP-1400527-A1 | Chiral diphosphorus compounds and transition metal complexes thereof | Bayer Chemicals AG (DE) | 2004-03-24 | — | — | EP | disclosed |
| EP-1398319-A1 | Chiral monophosphorus compounds and transition metal complexes thereof | Bayer Chemicals AG (DE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1232279-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINES | BASF AKTIENGESELLSCHAFT (DE) | 2002-08-21 | — | — | EP | disclosed |
| EP-0906324-B1 | CARBOHYDRATE DERIVATIVES AND THEIR SOLID-PHASE SYNTHESIS | BASF AG (DE) | 2001-08-01 | — | — | EP | disclosed |
| US-6242583-B1 | COUPLING CARBOHYDRATE COMPOUNDS IN PRESENCE OF PROMOTER TO A FUNCTIONALIZED SOLID SUPPORT | BASF AKTIENGESELLSCHAFT (DE) | 2001-06-05 | — | — | US | disclosed |
| WO-2001038292-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINES | BASF AKTIENGESELLSCHAFT (DE) | 2001-05-31 | — | — | WO | disclosed |
| US-5990320-A | Optically active diphosphine ligands | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-23 | — | — | US | disclosed |
| EP-0906324-A1 | CARBOHYDRATE DERIVATIVES AND THEIR SOLID-PHASE SYNTHESIS | BASF AKTIENGESELLSCHAFT (DE) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997045436-A1 | CARBOHYDRATE DERIVATIVES AND THEIR SOLID-PHASE SYNTHESIS | BASF AKTIENGESELLSCHAFT (DE) | 1997-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280066-A1 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | APP, BACE1, APH1A | MAPK1 1262/4885TSHR 4201/4885ALDH1A1 2920/4885 |
| US-20040127430-A1 | Chiral monophosphorus compounds and their transition metal complexes | MDM4, MPHOSPH6, AP3M1 | MAPK1 3512/4885TSHR 4810/4885ALDH1A1 4060/4885 |
| US-20070197624-A1 | Acylated amino acid amidyl pyrazoles and related compounds | APP, BACE1, APH1A | MAPK1 1262/4885TSHR 4201/4885ALDH1A1 2920/4885 |
| US-20070155971-A1 | Chiral diphosphorus compounds and their transition metal complexes | CDIPT, DCPS, PIN1 | MAPK1 3145/4885TSHR 4720/4885ALDH1A1 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.